AMRX — Amneal Pharmaceuticals, Inc. stock price, charts and financials

QT78Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
18.85
+0.53+2.89%
AMRXQT78Amneal Pharmaceuticals, Inc.·NASDAQ
18.85+2.89%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E37.58EPS (ttm)0.49Insider Own-Shs Outstand319.33MPerf Week2.23%
Market Cap5.85BForward P/E15.62EPS next Y1.17Insider Trans-0.02%Shs Float163.57MPerf Month7.96%
Enterprise Value8.51BPEG0.01EPS next Q-Inst Own-Short Float4.96%Perf Quarter42.35%
Income157.95MP/S1.88EPS this Y160.42%Inst Trans-Short Ratio4.24Perf Half Y29.84%
Sales3.12BP/B177.08EPS next Y18.49%ROA4.17%Short Interest8.12MPerf YTD45.40%
Book/sh-P/C26.58EPS next 5Y19.55%ROE-327.25%52W High19.82 -4.88%Perf Year127.01%
Cash/sh-P/FCF39.54EPS past 3/5Y- -18.45%ROIC8.18%52W Low7.89 138.85%Perf 3Y500.66%
Dividend Est.-EV/EBITDA19.01Sales past 3/5Y10.92% 8.66%Gross Margin39.32%Volatility3.02% 3.18%Perf 5Y279.30%
Dividend TTM-EV/Sales2.73EPS Y/Y TTM200.00%Oper. Margin7.91%ATR (14)0.62Perf 10Y-
Dividend Ex-Date-Quick Ratio1.44Sales Y/Y TTM9.06%Profit Margin5.06%RSI (14)61.00Recom2.35
Dividend Gr. 3/5Y-Current Ratio2.20EPS Q/Q28.57%SMA203.52%Beta1.25Target Price19.25
Payout0.00%Debt/Eq84.54Sales Q/Q4.03%SMA5014.08%Rel Volume1.04Prev Close18.32
Employees8,500LT Debt/Eq452.50EarningsOct 29SMA20035.89%Avg Volume1.94MPrice18.85
IPO DateMay 07, 2018Option/ShortYes / YesEPS/Sales Surpr.59.64% 0.40%Net Debt/EBITDA5.95Volume2,011,709Change2.89%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-31-26ReiteratedGoldman SachsBuy$19$21
Jul-15-26ReiteratedUBSBuy$19$23
May-20-26ReiteratedBarclaysOverweight$15$16
Apr-17-26InitiatedUBSBuy$19
Mar-02-26ReiteratedTruist SecuritiesBuy$15$17
Jan-07-26ReiteratedTruist FinancialBuy$14$15
Dec-08-25InitiatedBarclaysOverweight$11$15
Mar-03-25ReiteratedBarclaysOverweight$11
Feb-24-25UpgradeJP MorganNeutralOverweight
Nov-11-24ReiteratedPiper SandlerOverweight$8.00$11
Latest News
Jul-31-26
Jul-30-26
Jul-24-26
Jul-23-26
Jul-22-26
Jul-21-26
Jul-17-26
Jul-15-26
Jul-09-26
Jul-08-26
Company

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,1183,0192,7942,3942,2122,0941,9931,6261,663
Cost of Goods Sold Incl. D&A1,8921,8831,7741,5301,4211,3251,3641,273947
Gross Profit1,2261,1361,020864791769628353716
Selling, General and Administrative Excl. Other620527476430400366327290230
Research and Development175186191195209210191202210
Other Operating Expense3701043427740191101
Operating Income248423249204-9515391-249-20
Interest Expense117241259211158136146168144
Unusual Expense
Non-Operating Income (Expense)72-43-46-3451519197-39
Net Income Before Taxes201139-55-40-24831-36-220-203
Income Taxes-1411198711-104383-1
Consolidated Net Income15772-117-84-1301191-362-170
Net Income From Continuing Operations204128-74-49-2552069-604-201
Net Income15772-117-84-1301191-362-170
EPS (Recurring)0.490.23-0.38-0.48-0.860.070.62-4.57-1.33
EPS (Basic, Before Extraordinaries)0.490.23-0.38-0.48-0.860.070.62-4.57-1.33
EPS (Diluted)0.490.22-0.38-0.48-0.860.070.61-4.57-1.33
EBITDA449604440501440401346155-20
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio38.4757.2768.437.49
Price To Sales Ratio1.931.310.880.440.140.340.340.391.03
Gross Margin39.3237.6336.5136.0935.7636.7231.5121.7143.05
Operating Margin7.9514.018.918.52-4.297.314.57-15.31-1.20
Net Margin5.042.38-4.19-3.51-5.880.534.57-22.26-10.22
Shares Outstanding319313309175151149149132127
Market Capitalization6,0133,9442,4471,0623007146816361,718
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$20.89$17.01$13.13$9.25$5.37 Close Price0.00M2.59M5.18M7.77M10.36MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Autor Deborah M.DirectorMay 11 '26Sale12.9434,819450,55893,660May 12
George Jeffrey P.DirectorMay 07 '26Option Exercise0.0034,8190344,614May 08
Patel GautamDirectorMay 07 '26Option Exercise0.0034,81901,643,963May 08
BUCHI J KEVINDirectorMay 07 '26Option Exercise0.0034,819075,077May 08
MEISTER PAUL MDirectorMay 07 '26Option Exercise0.0048,7470832,800May 08
Kiely JohnDirectorMay 07 '26Option Exercise0.0034,8190260,252May 08
Nark Ted CDirectorMay 07 '26Option Exercise0.0034,8190325,848May 08
Yanai ShlomoDirectorMay 07 '26Option Exercise0.0034,8190320,804May 08
Autor Deborah M.DirectorMay 07 '26Option Exercise0.0034,8190128,479May 08
Shah NikitaExecutive Vice PresidentMar 04 '26Option Exercise0.0035,8800417,769Mar 05
Konidaris TasosExecutive Vice President & CFOMar 04 '26Option Exercise0.0093,9640471,469Mar 05
Patel ChintuCo-CEOMar 04 '26Option Exercise0.0092,59301,417,504Mar 05
BOYER ANDREW SExecutive Vice PresidentMar 04 '26Option Exercise0.0038,1950445,208Mar 05
Patel Chirag K.President & Co-CEOMar 04 '26Option Exercise0.0092,59301,431,295Mar 05
Daly Jason B.EVP, Chief Legal OfficerMar 04 '26Option Exercise0.0035,8800267,364Mar 05
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.